Cabinet libéral
- Address
- 20 rue des Vicaires, 59800 Lille, France
Cabinet libéral - Bladder Cancer Research
This independent medical practice specializes in clinical research focused on urological oncology, with particular expertise in the treatment of bladder cancer. The center participates in advanced Phase III trials investigating novel therapeutic approaches for patients with high-risk non-muscle invasive disease.
- High-risk non-muscle invasive bladder cancer (NMIBC) treatment strategies
- Combination immunotherapy approaches with BCG (Bacillus Calmette-Guerin)
- Evaluation of atezolizumab efficacy in urological malignancies
The practice is actively involved in evaluating cutting-edge treatment protocols that combine traditional intravesical BCG therapy with modern immunotherapy agents. Research efforts focus on improving event-free survival outcomes for patients following transurethral resection of the bladder (TURBT), contributing to the advancement of personalized treatment strategies in bladder cancer management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Unicancer1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cabinet libéral
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized Trial of Atezolizumab Plus BCG Versus BCG Alone in High-Risk Non-Muscle Invasive Bladder Cancer Patients | Unicancer | Phase III | Not Yet Recruiting | — | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.